Hong Kong is currently the only location in Asia to offer histotripsy — the world’s first non-invasive, non-thermal, surgery-free method for destroying tumours using focused sound waves. 

This technology is particularly life-changing for patients who are not suitable for surgery, have tumours in delicate or high-risk locations, or have been told they have limited options.

Cancer treatments have evolved rapidly over the past decade, yet most patients in Asia still face the same traditional pathway: surgery, chemotherapy, radiotherapy, or thermal ablation. Each comes with risks, side effects, and recovery time that can be difficult, especially for people who are older, medically fragile, or whose tumours sit near vital structures.

Today, a completely new class of treatment has arrived. Histotripsy is the world’s first true non-invasive, non-thermal, incision-free method for destroying tumours and is available in Asia exclusively in Hong Kong. And for many patients who have been told “surgery is too risky” or “there are limited options left,” this breakthrough offers a new path forward.

Hong Kong Leads Asia in Bringing Histotripsy to Patients

Hong Kong has become the first and only location in Asia to introduce the HistoSonics™ histotripsy system, a technology already cleared by the US FDA and backed by extensive research.

This early adoption didn’t happen by chance.

Hong Kong’s healthcare ecosystem has several strengths that set it apart:

Hong Kong’s regulatory framework allows advanced treatments to be evaluated and approved sooner than in most neighbouring countries. This means patients gain access years before widespread regional adoption.

Leading institutions like The Chinese University of Hong Kong (CUHK), HK Sanatorium & Hospital, and Gleneagles Hospital have long-standing collaborations with clinical researchers and medical device innovators around the world.

Why Histotripsy Matters Most for Patients Who Cannot Undergo Surgery

Ideal for High-Risk or “Inoperable” Cases

Because histotripsy uses sound waves rather than heat or scalpels, it avoids damaging the surrounding tissue. Tumours close to blood vessels — traditionally very risky to remove — can now be treated more safely.

A Second Chance for Patients Previously Told to “Wait and Watch”

Patients who were only eligible for palliative care or monitoring now have an active treatment option that is non-invasive and low risk.

Better Quality of Life

With minimal discomfort and no recovery from major surgery, patients—especially the elderly—experience far less disruption to daily life.

Why Other Countries in Asia Don’t Have Histotripsy Yet

Many countries in Asia have strong oncology systems, but histotripsy requires:

• dedicated specialist training

• advanced imaging capabilities

• high regulatory thresholds

• robust clinical trial participation

• integration with multidisciplinary cancer teams

Hong Kong was uniquely positioned to meet these requirements early. Neighbouring regions such as Singapore, Malaysia, Japan, and China are currently evaluating or trialling histotripsy, but none have reached commercial availability.

That places Hong Kong at the forefront of a major shift in non-invasive cancer care. 

Histotripsy marks a turning point in tumour treatment — not just technologically, but emotionally. For many patients, it brings renewed confidence, freedom from invasive surgery, and a safer path toward healing.

As adoption expands globally, Hong Kong is leading the region into a new era of precision-guided, non-invasive cancer therapy — offering hope to patients who once felt they had none.